



Pharmacy Quality Assurance Commission
PO Box 47852 Olympia, WA 98504
www.doh.wa.gov · TDD Relay: 711

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email doh.information@doh.wa.gov.

February 13, 2026 Weekly Legislative Review Agenda

Time: 12:00 p.m. – 1:00 p.m.
Location: Zoom ID: **863 0929 9195**
<https://us02web.zoom.us/j/86309299195>
Or One tap mobile :
+12532050468,,86309299195# US
+12532158782,,86309299195# US (Tacoma)
In Person: Department of Health
[111 Israel Rd SE](#), #140 (TC2)
Tumwater WA 98501
Contact: Joshua Munroe, Rules and Legislative Consultant, 360.502.5058
Joshua.Munroe@doh.wa.gov
Commission Office: wspqac@doh.wa.gov

No registration needed. **All attendees will join the call with their audio connection muted.**

12:00 p.m.

1. Call to Order
 - 1.1. Roll Call
2. PQAC Bill Report
3. Public Comment Period

1:00 PM (approximately)
Meeting Adjourned

[Link to Washington State Legislature Bill Information 2026](#)

Monday, January 12 – First day of session
 Wednesday, February 4 – Policy committee cutoff
 Monday, February 9 – Fiscal committee cutoff
 Tuesday, February 17 – House of origin cutoff **Next cutoff**

Wednesday, February 25 – Policy committee cutoff (opposite house)
 Monday, March 2 – Fiscal committee cutoff (opposite house)
 Friday, March 6 – Opposite house cutoff
 Thursday, March 12 – Sine die: Last day allowed for regular session under state constitution

TVW - <http://www.tvw.org/>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
SSB 5924	Expanding prescriptive authority for pharmacists	<p>Pharmacists that wish to exercise certain diagnosis and prescriptive authority must enter into a collaborative drug therapy agreement (CDTA) with a licensed physician under current statute. This bill expands the prescriptive authority for pharmacists licensed and practicing in Washington by amending the “practice of pharmacy.” The definition for “practice of pharmacy” in RCW 18.64.011(32) is amended to include “diagnosing and the prescribing or ordering of drugs and devices based on his or her education, training, and experience” as permitted under a pharmacist’s scope of practice.</p> <p>RCW 69.41.030 is also amended to remove a qualifying statement for pharmacists that references a CDTA being a necessary condition for a pharmacist to issue an order or prescription for a legend drug.</p>	<p>SSB 5924 <i>Sponsor(s):</i> Senators Slatter, Short, Chapman, Conway, Hasegawa, Nobles, Orwall, Riccelli, Saldaña, and Shewmake</p> <p><i>Public Hearing (Health & Long-Term Care):</i> 1/30/2026 <i>Executive Session (Health & Long-Term Care):</i> 2/3/2026, substitute adopted and passed through committee with a DO PASS recommendation. Passed to Rules Committee for second reading (2/4). <i>Second Reading (Rules):</i> 2/6/2026</p>
HB 2176	Exempting info in CDTAs from disclosure under the Public Records Act	<p>This bill amends RCW 42.56.360 to exempt collaborative drug therapy agreements (CDTAs) from disclosure under the public records act. Information contained in CDTAs, as well as any attachments or appendices to those CDTAs, are considered confidential and may not be disclosed except under the circumstances outlined in subsection 6(b).</p> <p>Per subsection 6(b), a CDTA or its associated contents may be disclosed if the CDTA is the basis of an order or stipulation finding misconduct</p>	<p>HB 2176 <i>Sponsor(s):</i> Representatives Thai, Parshley, Ryu, Reed, Zahn, Gregerson, Reeves, and Fosse</p> <p><i>Introduction (House):</i> 1/12/2026, referred to Committee on State Government & Tribal Relations.</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
		resulting in disciplinary action, though personally identifiable information of individuals not facing discipline is still confidential and may not be disclosed. "Personally identifiable information" is defined to include names, mailing addresses, credential numbers, email addresses, practice site facility addresses, and practice site facility phone numbers.	<i>Public Hearing (State Government & Tribal Relations): 1/14/2026</i> <i>Executive Session (State Government & Tribal Relations): 1/28/2026,</i> passed through committee with a DO PASS recommendation. Referred to Rules 2 Review (2/2).
2SSB 5968	Integrating executive order 25-03 to improve regulatory efficiency	Companion bill to HB 2198. The substitute version of SB 5968 adds the Department of Natural Resources to the list of agencies and adjusts phrasing relating to the intentionality of failing to provide necessary reporting information under the rule.	2SSB 5968 <i>Sponsor(s):</i> Senators Krishnadasan, Liias, and Shewmake <i>Second Reading (Rules): 1/28/2026,</i> placed on consent calendar. Referred to Ways & Means (2/3). <i>Public Hearing (Ways & Means): 2/5/2026</i> <i>Executive Session (Ways & Means): 2/9/2026,</i> second substitute adopted and passed through committee with a DO PASS recommendation. Passed to Rules Committee for second reading.

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
SB 5988 Agency request	Establishing fee authority for accreditation services provided to opioid treatment programs	SB 5988 allows DOH to apply to the federal Department of Health and Human Services for approval to accredit opioid treatment programs (OTPs). If approved, the department will execute its responsibilities as an accrediting body according to HHS policies and procedures and establish OTP accreditation fees in rule.	SB 5988 <i>Sponsor(s):</i> Senator Robinson; by request of Department of Health <i>Executive Session (Ways & Means):</i> 2/3/2026, no action taken <i>2nd Executive Session (Ways & Means):</i> 2/9/2026, passed through committee with a DO PASS recommendation. <i>Second Reading (Rules):</i> 2/10/2026

Additional Bills to Watch			
Bill # /Companion	Short Title		Committee Action (subject to change)
2SHB 2145	Protecting patient access to discounted medications and health care services – 340B drug pricing program	2SHB 2145 <i>Sponsor(s):</i> Representatives Thai, Macri, Obras, Parshley, Tharinger, Salahuddin, Stonier, Berry, Zahn, Bergquist, Lekanoff, Fosse, Stearns, Entenman, Duerr, Wylie, Reed, Fey, Hill, Pollet, Santos, Taylor, Hall, Bernbaum, Berg, Ormsby, Reeves, Ryu, Kloba, Ramel, Doglio, Mena, Cortes, Street, Scott, Thomas, Morgan, Gregerson, Goodman, Farivar, and Davis <i>Executive Session (Health Care & Wellness):</i> 1/23/2026; substitute adopted and passed through committee with a DO PASS recommendation. Referred to Appropriations (1/28). <i>Public Hearing (Appropriations):</i> 2/6/2026 <i>Executive Session (Appropriations):</i> 2/9/2026, second substitute adopted and passed through committee with a DO PASS recommendation. Referred to Rules 2 Review.	
2SSB 5981	Protecting patient access to discounted medications and	2SSB 5981 <i>Sponsor(s):</i> Senators Cleveland, Slatter, Harris, Bateman, Alvarado, Chapman, Dhingra, Frame, Hasegawa, Liias, Nobles, Pedersen, Saldaña, and Valdez	

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
	health care services – 340B drug pricing program	<i>Public Hearing (Ways & Means): 2/5/2026</i> <i>Executive Session (Ways & Means): 2/9/2026</i> , second substitute adopted and passed through committee with a DO PASS recommendation. Passed to Rules Committee for second reading. <i>Second Reading (Rules): 2/10/2026</i>
SHB 2152	Medical use of cannabis by qualifying patients in specified health care facilities	SHB 2152 <i>Sponsor(s):</i> Representatives Kloba, Rude, Parshley, Ryu, Chase, Callan, Jacobsen, Fosse, Doglio, Simmons, Scott, Pederson, Reed, Obras, Fitzgibbon, Cortes, Zahn, Wylie, Morgan, Gregerson, Reeves, Farivar, Hill, and Donaghy <i>Introduction (House): 1/12/2026</i> , referred to Committee on Health Care & Wellness. <i>Public Hearing (Health Care & Wellness): 1/13/2026</i> <i>Executive Session (Health Care & Wellness): 1/21/2026</i> , substitute adopted and passed through committee with a DO PASS recommendation; referred to Rules 2 Review (1/26). <i>Floor Vote (House): 2/10/2026</i> , passed through chamber via majority vote (89/6/0/3) .
SHB 2157	Regulating high-risk AI system development	SHB 2157 <i>Sponsor(s):</i> Representatives Ryu, Stearns, Ramel, Parshley, Reeves, Reed, Santos, Zahn, Street, Duerr, Gregerson, Ormsby, Scott, Shavers, Thai, Macri, Fosse, Pollet, and Donaghy <i>Public Hearing (Technology, Economic Development & Veterans): 1/14/2026</i> <i>Executive Session (Technology, Economic Development & Veterans): 1/23/2026</i> , no action taken <i>2nd Executive Session (Technology, Economic Development & Veterans): 1/27/2026</i> , substitute adopted and passed through committee with a DO PASS recommendation. Referred to Rules 2 Review (1/30).
SSB 5951	Expanding access to albuterol in public and private schools	SSB 5951 <i>Sponsor(s):</i> Senators Cortes, Nobles, Orwall, Slatter, Stanford, and C. Wilson <i>Introduction (Senate): 1/12/2026</i> , referred to Committee on Early Learning & K-12 Education <i>Public Hearing (Early Learning & K-12 Education): 1/21/2026</i> <i>Executive Session (Early Learning & K-12 Education): 1/29/2026</i> , passed through committee with a DO PASS recommendation. Passed to Rules Committee for second reading (1/30).

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
SHB 2360	Expanding access to albuterol in public and private schools	<p>SHB 2360 <i>Sponsor(s)</i>: Representatives Donaghy, Reed, Engell, Bronoske, Zahn, Thomas, Ormsby, Fosse, Salahuddin, Hill, and Pollet</p> <p><i>Public Hearing (Education)</i>: 1/19/2026 <i>Executive Session (Education)</i>: 2/2/2026, substitute adopted and passed through committee with a DO PASS recommendation. Referred to Rules 2 Review (2/4). <i>Second Reading (Rules)</i>: 2/10/2026, Rules Committee relieved of further consideration.</p>
SHB 2242	Preserving access to preventative services by clarifying state authority and definitions	<p>SHB 2242 <i>Sponsor(s)</i>: Representatives Bronoske, Doglio, Parshley, Simmons, Berry, Ramel, Thomas, Ormsby, Thai, Macri, Fosse, Pollet, Obras, Wylie, and Zahn; by request of Governor Ferguson and the Insurance Commissioner</p> <p><i>Executive Session (Health Care & Wellness)</i>: 1/23/2026, no action taken <i>2nd Executive Session (Health Care & Wellness)</i>: 1/28/2026, substitute adopted and passed through committee with a DO PASS recommendation. Referred to Rules 2 Review (1/30). <i>Second Reading (Rules)</i>: 2/6/2026, Rules Committee relieved of further consideration.</p>
SB 5967	Preserving access to preventative services by clarifying state authority and definitions	<p>SB 5967 <i>Sponsor(s)</i>: Senators Cleveland, Harris, Hasegawa, Liias, and Pedersen; by request of Governor Ferguson and the Insurance Commissioner</p> <p><i>Introduction (Senate)</i>: 1/12/2026, referred to Committee on Health & Long-Term Care <i>Public Hearing (Health & Long-Term Care)</i>: 1/15/2026 <i>Executive Session (Health & Long-Term Care)</i>: 1/20/2026, passed through committee by majority vote; passed to Rules Committee for second reading (1/22).</p>
SHB 2247	Veterinarian-client-patient relationships	<p>SHB 2247 <i>Sponsor(s)</i>: Representatives Parshley, Lekanoff, Reed, Leavitt, Zahn, Gregerson, Berg, and Fosse</p> <p><i>Introduction (House)</i>: 1/12/2026, referred to Committee on Health Care & Wellness <i>Public Hearing (Health Care & Wellness)</i>: 1/14/2026</p>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
		<i>Executive Session (Health Care & Wellness): 1/23/2026, substitute adopted and passed through committee with a DO PASS recommendation. Referred to Rules 2 Review (1/27).</i>
HB 2453	Psychiatric pharmacists in 23-hour crisis relief centers	<p>HB 2453 <i>Sponsor(s):</i> Representatives Farivar, Thai, Scott, and Reed</p> <p><i>Introduction (House):</i> 1/13/2026, referred to Committee on Civil Rights & Judiciary <i>Public Hearing (Civil Rights & Judiciary):</i> 1/27/2026 <i>Executive Session (Civil Rights & Judiciary):</i> 2/3/2026, passed through committee with a DO PASS recommendation. Referred to Rules 2 Review (2/4).</p>
SSB 5112	Establishing a prescribing psychologist certification	<p>SSB 5112 <i>Sponsor(s):</i> Senators Bateman, Harris, Shewmake, Trudeau, Conway, Nobles, Riccelli, C. Wilson, Robinson, and Hasegawa</p> <p><i>Re-Introduction (Senate):</i> 1/12/2026, retained in present status (Rules Committee)</p>
3SSB 5387	Corporate practice of medicine	<p>3SSB 5387 <i>Sponsor(s):</i> Senators Robinson, Hasegawa, Lias, Nobles, Riccelli, Stanford, and Valdez</p> <p><i>Re-Introduction (Senate):</i> 1/12/2026, Rules Committee relieved of further consideration. On motion, referred to Ways & Means. <i>Public Hearing (Ways & Means):</i> 2/5/2026 <i>Executive Session (Ways & Means):</i> 2/9/2026, third substitute adopted and passed through committee with a DO PASS recommendation. Passed to Rules Committee for second reading.</p>
E2SSB 5594	Biosimilar medicines and interchangeable biological products	<p>E2SSB 5594 <i>Sponsor(s):</i> Senators Harris, Cleveland, Hasegawa, and Shewmake</p> <p><i>Floor Vote (Senate):</i> 1/21/2026, floor amendment adopted and bill passed by majority vote (49/0/0).</p> <p><i>First Reading (House):</i> 1/26/2026, referred to Committee on Health Care & Wellness. <i>Public Hearing (Health Care & Wellness):</i> 2/10/2026</p>

Dead/dormant Bills (relevant if needed to pass the budget)		
Bill # /Companion	Short Title	Bill Summary
HB 2613	Safety and regulatory requirements for compounded medications	<p>HB 2613 <i>Sponsor(s):</i> Representatives Thai, Parshley, Duerr, Santos, Ormsby, and Hill <i>Introduction (House):</i> 1/21/2026, referred to Committee on Health Care & Wellness. <i>Public Hearing (Health Care & Wellness):</i> 1/30/2026</p> <p>Missed Cutoff Date: 2/4/2026 (house-of-origin policy committee)</p>
HB 2302	Expanding prescriptive authority for pharmacists	<p>HB 2302 <i>Sponsor(s):</i> Representatives Thai, Macri, Reed, Zahn, Thomas, Stonier, Ormsby, and Hill <i>Pre-file (House):</i> 1/7/2026 <i>Introduction (House):</i> 1/12/2026, referred to Committee on Health Care & Wellness.</p>
SB 5900	Medical use of cannabis by qualifying patients in specified health care facilities	<p>SB 5900 <i>Sponsor(s):</i> Senators Riccelli, Robinson, Hasegawa, Nobles, Saldaña, and C. Wilson <i>Pre-file (Senate):</i> 12/16/2025 <i>Introduction (Senate):</i> 1/12/2026, referred to Committee on Health & Long-Term Care.</p>
SB 6072	Veterinarian-client-patient relationships	<p>SB 6072 <i>Sponsor(s):</i> Senators Cleveland, Warnick, and Nobles <i>Introduction (Senate):</i> 1/13/2026, referred to Committee on Health & Long-Term Care <i>Public Hearing (Health & Long-Term Care):</i> 1/23/2026</p>

Dead/dormant Bills (relevant if needed to pass the budget)		
Bill # /Companion	Short Title	Bill Summary
HB 2261	Ensuring transparency in credentials and communications between patients and health care professionals	<p>HB 2261 <i>Sponsor(s):</i> Representatives Marshall and Barnard</p> <p><i>Introduction (House):</i> 1/12/2026, referred to Committee on Health Care & Wellness <i>Public Hearing (Health Care & Wellness):</i> 1/21/2026 <i>Executive Session (Health Care & Wellness):</i> 1/28/2026, no action taken.</p>
SB 6166	Ensuring transparency in credentials and communications between patients and health care professionals	<p>SB 6166 <i>Sponsor(s):</i> Senators Muzzall and Chapman</p> <p><i>Introduction (Senate):</i> 1/15/2026, referred to Committee on Health & Long-Term Care</p>
HB 2291	Kratom consumer protection act	<p>HB 2291 <i>Sponsor(s):</i> Representatives Reeves, Stonier, Parshley, Leavitt, Gregerson, Goodman, Fosse, Pollet, and Bernbaum</p> <p><i>Introduction (House):</i> 1/12/2026, referred to Committee on Consumer Protection & Business <i>Public Hearing (Consumer Protection & Business):</i> 1/30/2026</p>
HB 2383	Involuntary treatment act	<p>HB 2383 <i>Sponsor(s):</i> Representatives Walsh and Graham</p> <p><i>Pre-file (House):</i> 1/9/2026 <i>Introduction (House):</i> 1/12/2026, referred to Committee on Civil Rights & Judiciary</p>
SB 5452	Licensing board-certified psychiatric pharmacists as agency-affiliated counselors	<p>SB 5452 <i>Sponsor(s):</i> Senators Slatter and Nobles</p> <p><i>Re-Introduction (Senate):</i> 1/12/2026, retained in present status (Committee on Health & Long-Term Care)</p>

Dead/dormant Bills (relevant if needed to pass the budget)		
Bill # /Companion	Short Title	Bill Summary
HB 1124	Establishing a prescribing psychologist certification	<p>HB 1124 <i>Sponsor(s):</i> Representatives Simmons, Macri, Senn, Stonier, Ormsby, Tharinger, Kloba, Duerr, Ryu, Morgan, Reed, Callan, Obras, Doglio, Ortiz-Self, Goodman, Reeves, and Hill</p> <p><i>Re-Introduction (House):</i> 1/12/2026, retained in present status (Committee on Health Care & Wellness)</p>
HB 1888	Naturopathic physician scope-of-practice	<p>HB 1888 <i>Sponsor(s):</i> Representatives Berg, Walen, Wylie, Doglio, Ryu, Parshley, Goodman, Santos, Morgan, Duerr, Ramel, Hill, and Macri</p> <p><i>Re-Introduction (House):</i> 1/12/2026, retained in present status (Committee on Health Care & Wellness)</p>
SB 5765	Psychiatric pharmacists	<p>SB 5765 <i>Sponsor(s):</i> Senators Slatter, Nobles, and Trudeau</p> <p><i>Re-Introduction (Senate):</i> 1/12/2026, retained in present status (Committee on Health Care & Wellness)</p>
HB 1675	Corporate practice of medicine	<p>HB 1675 <i>Sponsor(s):</i> Representatives Thai and Macri</p> <p><i>Re-Introduction (House):</i> 1/12/2026, retained in present status (Committee on Health Care & Wellness)</p>
SB 6254	Leveraging AI to streamline regulatory language	<p>SB 6254 <i>Sponsor(s):</i> Senators Braun, Boehnke, Gildon, and Wellman</p> <p><i>Introduction (Senate):</i> 1/21/2026, referred to Committee on State Government, Tribal Affairs & Elections.</p>

Dead/dormant Bills (relevant if needed to pass the budget)		
Bill # /Companion	Short Title	Bill Summary
HB 2198	Integrating executive order 25-03 to improve regulatory efficiency	<p>HB 2198 <i>Sponsor(s):</i> Representatives Richards, Leavitt, Ryu, Dufault, Zahn, Rule, Bronoske, Reeves, and Fosse</p> <p><i>Introduction (House):</i> 1/12/2026, referred to Committee on State Government & Tribal Relations. <i>Public Hearing (State Government & Tribal Relations):</i> 1/23/2026 <i>Executive Session (State Government & Tribal Relations):</i> 2/3/2026, passed through committee with a DO PASS recommendation. Referred to Appropriations (2/4).</p> <p>Missed Cutoff Date: 2/9/2026, (house-of-origin fiscal committee)</p>
SB 5921	Psilocybin program	<p>SB 5921 <i>Sponsor(s):</i> Senators Salomon, Lovelett, Nobles, Riccelli, Saldaña, Shewmake, and Slatter</p> <p><i>Introduction (Senate):</i> 1/12/2026, referred to Committee on Health & Long-Term Care. <i>Public Hearing (Health & Long-Term Care):</i> 1/27/2026 <i>Executive Session (Health & Long-Term Care):</i> 2/3/2026, passed through committee with a DO PASS recommendation. Referred to Ways & Means (2/4).</p> <p>Missed Cutoff Date: 2/9/2026, (house-of-origin fiscal committee)</p>
HB 2437 Agency request	Establishing fee authority for accreditation services provided to opioid treatment programs	<p>HB 2437 <i>Sponsor(s):</i> Representatives Lekanoff, Parshley, Ryu, Peterson, Simmons, Ramel, Davis, Macri, and Nance; by request of Department of Health</p> <p><i>Introduction (House):</i> 1/13/2026, referred to Committee on Health Care & Wellness. <i>Public Hearing (Health Care & Wellness):</i> 1/20/2026 <i>Executive Session (Health Care & Wellness):</i> 1/30/2026, passed through committee with a DO PASS recommendation. Referred to Appropriations (2/3).</p> <p>Missed Cutoff Date: 2/9/2026, (house-of-origin fiscal committee)</p>
SSB 6287	Preparation, distribution, and sale of kratom products	<p>SSB 6287 <i>Sponsor(s):</i> Senator Salomon</p>

Dead/dormant Bills (relevant if needed to pass the budget)		
Bill # /Companion	Short Title	Bill Summary
		<p><i>Introduction (Senate): 1/22/2026, referred to Committee on Labor & Commerce.</i></p> <p><i>Public Hearing (Labor & Commerce): 1/27/2026</i></p> <p><i>Executive Session (Labor & Commerce): 2/3/2026, substitute adopted and passed through committee with a DO PASS recommendation. Referred to Ways & Means (2/4).</i></p> <p><i>Public Hearing (Ways & Means): 2/6/2026</i></p> <p>Missed Cutoff Date: 2/9/2026, (house-of-origin fiscal committee)</p>